Form 4: LivaNova PLC: Chief Innovation Officer Receives Stock Grants

Ahmet Tezel, Chief Innovation Officer of LivaNova PLC, reports the acquisition of restricted stock units, performance stock units, and stock appreciation rights.

Summary

• On June 15, 2024, Ahmet Tezel, the Chief Innovation Officer of LivaNova PLC, was granted several forms of equity compensation.
• These include 11,863 restricted stock units (RSUs) that vest in equal annual installments over four years, starting June 15, 2025.
• He also received 3,559 performance stock units (PSUs) tied to the company's free cash flow (FCF) performance from 2024-2026, 3,559 PSUs tied to Return on Invested Capital (ROIC) performance from 2024-2026, and 7,118 PSUs tied to the company's total shareholder return (TSR) relative to an index of companies from January 1, 2024, to December 31, 2026.
• Additionally, Tezel was granted 25,383 stock appreciation rights (SARs) that vest in equal annual installments over four years, starting June 15, 2025, with an exercise price of $52.68 and an expiration date of June 15, 2034.
• All grants are subject to the terms of the company's 2022 Incentive Award Plan and the respective award agreements.

Sentiment

Score: 7

Explanation: The document itself is neutral, simply reporting equity grants. However, the grants suggest confidence in the executive's ability to contribute to the company's future success, which is mildly positive.

Positives

• The equity grants align the executive's interests with those of the shareholders, incentivizing performance improvements in free cash flow, return on invested capital, and total shareholder return.
• The vesting schedules encourage long-term commitment from the Chief Innovation Officer.

Risks

• The value of the stock appreciation rights is dependent on the future stock price of LivaNova PLC.
• The performance stock units are contingent on achieving specific financial targets, which may not be met.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules and performance periods associated with the equity grants.

Industry Context

Equity grants are a common practice in publicly traded companies to incentivize executives and align their interests with those of shareholders. The specific metrics used for the performance stock units (FCF, ROIC, TSR) reflect the company's strategic priorities.

Comparison to Industry Standards

• LivaNova's use of RSUs, PSUs, and SARs is consistent with compensation practices at comparable medical device companies such as Medtronic, Boston Scientific, and Abbott.
• Vesting schedules and performance metrics are typically tailored to the specific goals and challenges of the company.
• For example, companies focusing on growth might emphasize TSR, while those prioritizing profitability might focus on FCF or ROIC.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with long-term value creation.
• Employees may see the grants as a sign of the company's commitment to rewarding performance.
• The grants have no immediate impact on customers, suppliers, or creditors.

Key Dates